Conference literature can be an important way to bridge the gap between different scientific specialties — and to broaden the general knowledge base of specialists
With its ability to help measure, collect, and interpret data for all stakeholders, Medical Affairs will play an increasingly important role.
What Kite and Novartis developed are known as autologous gene therapies. What Allogene is pursuing is an allogeneic therapy.
The new Right to Try legislation comes as a culmination of a movement that has resulted in similar laws in 40 states. However, the new law has drawn fire from a variety of healthcare stakeholders who worry about the consequences of bypassing current FDA protocols — potential harm to patients and increased liability
The Department of Health and Human Services (HHS) published a Proposed Rule on May 7th asking for a one-year delay for implementing the January 2017 final rule under the 304B Drug Pricing Program. The delay has been granted